MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial

BACKGROUND: The Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS/NCT00651456) phase 3 trial demonstrated the superiority of bevacizumab plus pemetrexed–cisplatin triplet over chemotherapy alone in 448 malignant pleural mesothelioma (MPM) patients. Here, we evaluated the prognostic role of Hippo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Maille, Elodie, Brosseau, Solenn, Hanoux, Vincent, Creveuil, Christian, Danel, Claire, Bergot, Emmanuel, Scherpereel, Arnaud, Mazières, Julien, Margery, Jacques, Greillier, Laurent, Audigier-Valette, Clarisse, Moro-Sibilot, Denis, Molinier, Olivier, Corre, Romain, Monnet, Isabelle, Gounant, Valérie, Langlais, Alexandra, Morin, Franck, Levallet, Guénaëlle, Zalcman, Gérard
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6461894/
https://ncbi.nlm.nih.gov/pubmed/30739911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0379-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados